Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700617 · ClinicalTrials.gov registry record · Early Phase 1
Cardiac Power Output in Cardiogenic Shock Patients
A Early Phase 1 study of Heart Failure and Cardiogenic Shock, sponsored by University of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05700617 is a Early Phase 1 study of Heart Failure and Cardiogenic Shock that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 5 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05700617, a Early Phase 1 study of Heart Failure and Cardiogenic Shock, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Conditions Studied
Interventions
- DRUG 1:1 Randomization to receive milrinone
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700617
The ClinicalTrials.gov registry entry for NCT05700617 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which 1:1 Randomization to receive milrinone is the first listed.
NCT05700617 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05700617 about?
NCT05700617 is a clinical study titled "Cardiac Power Output in Cardiogenic Shock Patients". The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
What is the current status of trial NCT05700617?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2023-07-06. Estimated completion is 2026-06.
What conditions does trial NCT05700617 study?
This clinical trial studies the following conditions: Heart Failure, Cardiogenic Shock.
What interventions are being tested in trial NCT05700617?
The interventions under investigation include: 1:1 Randomization to receive milrinone (DRUG).
Who is sponsoring clinical trial NCT05700617?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05700617 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diffusion MRI in Heart Failure
RECRUITING · Early Phase 1
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.